Literature DB >> 17919665

Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats.

Chun-Qing Liu1, Zhong Chen, Fu-Xin Liu, Dan-Na Hu, Jian-Hong Luo.   

Abstract

Previous studies have suggested that brain histamine is involved in the pathogenesis of Parkinson's disease (PD), but the role of endogenous histamine in the degeneration of dopaminergic neurons in the substantia nigra pars compact (SNpc) remains unclear. We aimed to investigate this issue by changing the brain histamine levels by giving histaminergic agents, and administrating histamine receptor antagonists in the PD animal model, i.e. the 6-hydroxydopamine (6-OHDA)-lesioned rat. In saline-treated animals, 6-OHDA infusion produced a progressive increase in apomorphine-induced turning rate and a loss of tyrosine hydroxylase immunoreactive (TH-ir) neurons in the SNpc. Histaminergic agents were given prior and daily for 1, 7 or 14 days after 6-OHDA infusion. Histidine (500 mg/kg, i.p.), a precursor of histamine, increased the turning rate (27% on day 7 and 26% on day 14, respectively; P<0.05) and also the loss of TH-ir neurons, but only on day 1 and 7 (67% vs 47% and 90.4% vs 74% loss, respectively; P<0.05). In contrast, alpha-fluoromethylhistidine (alpha-FMH, 25 microg, i.c.v.), an irreversible inhibitor of histidine decarboxylase (HDC), significantly decreased the turning rate (25% on day 7 and 26% on day 14, respectively; P<0.05) and prevented the loss of TH-ir neurons, also only on day 1 and day 7 (28% vs 47% and 58% vs 74% loss, respectively; P<0.05). In addition, the histamine H(1) receptor antagonist pyrilamine (5 microg, i.c.v.), but not the H(2) receptor antagonist cimetidine (5 microg, i.c.v.), also decreased the turning rate (38% on day 7 and 21% on day 14, respectively; P<0.05) and prevented the loss of TH-ir neurons on day 1 and day 7 (38% vs 51% and 60% vs 78% loss, respectively; P<0.05). On day 14 after 6-OHDA lesion, there were no significant differences in the number of TH-ir neurons among all the different treatment groups. Taken together, these findings indicate that endogenous histamine may accelerate the degeneration of dopaminergic neurons via its H(1) receptor, while attenuation of histamine transmission may play a protective role on it in the early stage of development of 6-OHDA lesioned PD rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17919665     DOI: 10.1016/j.neuropharm.2007.08.014

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

1.  Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP+ Toxicity In Vivo.

Authors:  Natalia Moreno-Galarza; Liliana Mendieta; Victoria Palafox-Sánchez; Mireia Herrando-Grabulosa; Carles Gil; Daniel I Limón; José Aguilera
Journal:  Neurotox Res       Date:  2018-02-19       Impact factor: 3.911

Review 2.  Histamine in the Crosstalk Between Innate Immune Cells and Neurons: Relevance for Brain Homeostasis and Disease.

Authors:  Liliana Bernardino
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 3.  Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep-Wake Cycle Disorder.

Authors:  Mera Alhusaini; Nermin Eissa; Ali K Saad; Rami Beiram; Bassem Sadek
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

Review 4.  Interactions of the histamine and hypocretin systems in CNS disorders.

Authors:  Ling Shan; Yves Dauvilliers; Jerome M Siegel
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

5.  Histamine impairs midbrain dopaminergic development in vivo by activating histamine type 1 receptors.

Authors:  Itzel Escobedo-Avila; Fernanda Vargas-Romero; Anayansi Molina-Hernández; Rodrigo López-González; Daniel Cortés; Juan A De Carlos; Iván Velasco
Journal:  Mol Brain       Date:  2014-08-12       Impact factor: 4.041

Review 6.  Thr105Ile (rs11558538) polymorphism in the histamine N-methyltransferase (HNMT) gene and risk for Parkinson disease: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Félix Javier Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

7.  Histamine: a new immunomodulatory player in the neuron-glia crosstalk.

Authors:  Sandra M Rocha; Joel Pires; Marta Esteves; Baltazar Graça; Liliana Bernardino
Journal:  Front Cell Neurosci       Date:  2014-04-30       Impact factor: 5.505

8.  Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease.

Authors:  Emma Thornton; Robert Vink
Journal:  Neural Regen Res       Date:  2015-09       Impact factor: 5.135

Review 9.  The Histaminergic System in Neuropsychiatric Disorders.

Authors:  Li Cheng; Jiaying Liu; Zhong Chen
Journal:  Biomolecules       Date:  2021-09-11

Review 10.  Changes in Histaminergic System in Neuropsychiatric Disorders and the Potential Treatment Consequences.

Authors:  Ling Shan; Dick F Swaab
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.